ISY-3-4 - Multi-gene assay “Curebest 95GC” for recurrence prediction for ER+/HER2-/n0 breast cancer patients

Abstract

In recent years, one of the priority questions in breast cancer research has been the prediction of recurrence for ER-positive, HER2-negative and node-negative (ER+/HER2-/n0) breast cancer patients. This is because the indication for adjuvant chemotherapy for such patients is often very difficult to determine on the basis of the results of conventional histological examinations including immunohistochemistry for ER, PR, HER2 and Ki67. Then by the comprehensive gene expression analysis of DNA microarray for 549 primary sites of ER+ breast cancer, we developed a multi-gene classifier “Curebest 95GC” to predict recurrence for ER+/HER2-/n0 breast cancer treated by adjuvant hormonal therapy alone. The merit of 95GC is to divide the Intermediate-risk patients of 21GC(Oncotype DX) furtherly into the two risk groups (High/Low-risk). 95GC: http://www.ncbi.nlm.nih.gov/pubmed/23884597 The other priority question has been the prediction of sensitivity to neo-adjuvant chemotherapy (NAC: P-FAC) and prognosis after NAC. However, it is very difficult to predict it with high NPV (negative predictive value). Then we also developed multi-gene classifiers to predict it precisely. IRSN23 is the sensitivity prediction model for NAC for ER positive and negative breast cancer, and MPCP155 is the prediction model for sensitivity to NAC and prognosis after NAC only for ER positive breast cancer. IRSN23: http://www.ncbi.nlm.nih.gov/pubmed/24356621 MPCP155: http://www.ncbi.nlm.nih.gov/pubmed/26052094 Such classifiers have been shown to be superior to conventional histological examination findings and “Curebest 95GC” has already commercially available and in practical use. Here we review these multi-gene classifiers with a special emphasis on “Curebest 95GC”.